Compare OPBK & FOCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPBK | FOCL |
|---|---|---|
| Founded | 2005 | 1979 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.9M | 222.4M |
| IPO Year | 2018 | 1998 |
| Metric | OPBK | FOCL |
|---|---|---|
| Price | $14.70 | $4.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $17.75 | $8.80 |
| AVG Volume (30 Days) | 30.7K | ★ 68.8K |
| Earning Date | 10-30-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.80% | N/A |
| EPS Growth | ★ 23.74 | N/A |
| EPS | ★ 1.02 | N/A |
| Revenue | $3,204,000.00 | ★ $70,527,000.00 |
| Revenue This Year | $9.63 | N/A |
| Revenue Next Year | $10.79 | $34.10 |
| P/E Ratio | $14.46 | ★ N/A |
| Revenue Growth | N/A | ★ 1.63 |
| 52 Week Low | $12.41 | $3.97 |
| 52 Week High | $16.83 | $6.40 |
| Indicator | OPBK | FOCL |
|---|---|---|
| Relative Strength Index (RSI) | 39.81 | 41.37 |
| Support Level | $13.57 | $4.01 |
| Resistance Level | $15.00 | $4.50 |
| Average True Range (ATR) | 0.26 | 0.26 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 8.67 | 11.39 |
OP Bancorp operates its commercial community banking activities through Open Bank its wholly owned banking subsidiary. It provides commercial banking services to small and medium-sized businesses, their owners, and retail customers, with a focus on the Korean-American community. The bank currently operate twelve full service branches: nine branches across Los Angeles and Orange Counties in California, as well as one branch each in Santa Clara, California; Carrollton, Texas; and Las Vegas, Nevada. Additionally, it maintains five loan production offices located in Pleasanton, California; Atlanta, Georgia; Aurora, Colorado; Lynnwood, Washington; and Fairfax, Virginia. Substantially all its business activities are conducted through the Bank.
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.